Partnering with exceptional research teams worldwide

Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe.

Developing therapeutics with the potential to both treat and prevent disease

Molecular alteration programs

Discovery & Preclinical Development

Target

Hit

Lead

Candidate

Clinical Development

Phase I

Phase II

Phase III

CAM-9782

Lead
Undisclosed
Lead
Driver: 
Short telomeres
Therapeutic Area: 
Oncology
Program Overview:

CAM-5746

Hit
Undisclosed
Hit
Driver: 
Loss of proteostasis
Therapeutic Area: 
Autoimmune Diseases
Program Overview:

CAM-5747

Hit
Undisclosed
Hit
Driver: 
Loss of proteostasis
Therapeutic Area: 
Rare Diseases
Program Overview:

Cellular dysfunction programs

Discovery & Preclinical Development

Target

Hit

Lead

Candidate

Clinical Development

Phase I

Phase II

Phase III

VTA-100

Candidate
Undisclosed
Candidate
Driver: 
Loss of tissue stem cells
Therapeutic Area: 
Rare Diseases
Collaborator: 
Program Overview:

Vita Therapeutics is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell technology. Vita utilizes iPSCs to engineer specific cell types designed to replace those that are defective in patients, focusing on two distinct methodologies to deliver these cells: an autologous approach, a patient-specific therapy; and a hypoimmunogenic approach, a universal cell designed to be used for all patients. Vita is committed to delivering long-term disease-modifying cell-engineered treatments for patients with high unmet medical needs.

VTA-200

Hit
Undisclosed
Hit
Driver: 
Loss of tissue stem cells
Therapeutic Area: 
Rare Diseases
Collaborator: 
Program Overview:

Vita Therapeutics is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell technology. Vita utilizes iPSCs to engineer specific cell types designed to replace those that are defective in patients, focusing on two distinct methodologies to deliver these cells: an autologous approach, a patient-specific therapy; and a hypoimmunogenic approach, a universal cell designed to be used for all patients. Vita is committed to delivering long-term disease-modifying cell-engineered treatments for patients with high unmet medical needs.

CAM-5130

Candidate
Undisclosed
Candidate
Driver: 
Overactive cell growth signals
Therapeutic Area: 
Collaborator: 
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

CAM-5131

Lead
Undisclosed
Lead
Driver: 
Overactive cell growth signals
Therapeutic Area: 
Collaborator: 
Program Overview:

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

CAM-7276

Candidate
Undisclosed
Candidate
Driver: 
Buildup of damaged cells
Therapeutic Area: 
Cardiovascular Diseases
Collaborator: 
Program Overview:

CAM-3594

Target
Undisclosed
Target
Driver: 
Overactive cell growth signals
Therapeutic Area: 
Metabolic Disorders
Collaborator: 
Program Overview:

CAM-2789

Target
Undisclosed
Target
Driver: 
Overactive cell growth signals
Therapeutic Area: 
Metabolic Disorders
Collaborator: 
Program Overview:

Tissue degeneration programs

Discovery & Preclinical Development

Target

Hit

Lead

Candidate

Clinical Development

Phase I

Phase II

Phase III

CAM-1108

Candidate
Undisclosed
Candidate
Driver: 
Non-regenerating adult tissues
Therapeutic Area: 
Rare Diseases
Collaborator: 
Program Overview:

CAM-7520

Lead
Undisclosed
Lead
Driver: 
Changes in endocrine signaling
Therapeutic Area: 
Collaborator: 
Program Overview:

CAM-6019

Lead
Undisclosed
Lead
Driver: 
Non-regenerating adult tissues
Therapeutic Area: 
Cardiovascular
Collaborator: 
Program Overview:

CAM-4628

Hit
Undisclosed
Hit
Driver: 
Stiffening of extracellular matrix
Therapeutic Area: 
Fibrotic Diseases
Collaborator: 
Aston University
Program Overview:

CAM-2634

Hit
Undisclosed
Hit
Driver: 
Stiffening of extracellular matrix
Therapeutic Area: 
Fibrotic Diseases
Collaborator: 
University of Twente
Program Overview:

CAM-4265

Hit
Undisclosed
Hit
Driver: 
Stiffening of extracellular matrix
Therapeutic Area: 
Fibrotic Diseases
Collaborator: 
Mayo Clinic
Program Overview: